Australia’s active vaccine safety system

  • 18 month booster

    AusVaxSafety completed pertussis (whooping cough) booster vaccine safety active surveillance this month after nearly three years of monthly active surveillance. No safety signal was identified in children receiving DTPa at 18 months or DTPa-IPV at 4 years, with data contributed by over 55,000 participating parents/carers. Vaccine safety results are available on the AusVaxSafety website.

     

     

    Last updated 13/12/2019

    28,547 Parents/carers responded to an SMS about their child’s health a
    few days after their 18 month pertussis booster vaccinations.

    84%
    reported no adverse events

    84%
    reported no adverse events


    16%
    reported any adverse
    event, including...


    1.7%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    4,579 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • 4 year booster

    AusVaxSafety completed pertussis (whooping cough) booster vaccine safety active surveillance this month after nearly three years of monthly active surveillance. No safety signal was identified in children receiving DTPa at 18 months or DTPa-IPV at 4 years, with data contributed by over 55,000 participating parents/carers. Vaccine safety results are available on the AusVaxSafety website.

     

     

    Last updated 13/12/2019

    27,045 Parents/carers responded to an SMS about their child’s health a
    few days after their 4 year pertussis booster vaccinations.

    79.7%
    reported no adverse events

    79.7%
    reported no adverse events


    20.3%
    reported any adverse
    event, including...


    1.7%
    who reported taking their child
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    5,485 parents/carers reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.

  • Pregnant women

    From 1 July 2018, maternal pertussis vaccine is being funded for pregnant women under the National Immunisation Program. AusVaxSafety is monitoring the safety of maternal pertussis vaccines in the days following immunisation. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here.

     

     

    Last updated 03/07/2020

    10,779 Pregnant women responded to an SMS about their health a
    few days after their maternal pertussis vaccinations.

    93.9%
    reported no adverse events

    93.9%
    reported no adverse events


    6.1%
    reported any adverse
    event, including...


    0.5%
    who reported going
    to a doctor or emergency
    department in the days after
    vaccination.

    The adverse events they reported were similar to the types of adverse events reported overall

     

    656 Pregnant women reported one or more adverse events.
    The most commonly reported were:



    These symptoms are known to occur after vaccination. They are generally mild and short-lived. These symptoms are also common in young children for other reasons (such as viral infection) and may not be related to vaccination.